middle.news
Amplia Therapeutics Advances Pancreatic Cancer Drug with Positive Trial Data and $27.5M Raise
1:37pm on Friday 29th of May, 2026 AEST
•
Healthcare
Read Story
Amplia Therapeutics Advances Pancreatic Cancer Drug with Positive Trial Data and $27.5M Raise
1:37pm on Friday 29th of May, 2026 AEST
Key Points
ACCENT trial shows 11.1 months median overall survival
Discontinued AMPLICITY trial due to FOLFIRINOX toxicity
$27.5 million capital raised to support clinical programs
Completed large-scale GMP manufacturing of narmafotinib
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE